Contact – +1-276-477-5910
 Email – info@supplydemandmarketresearch.com

Home >>

Aerospace & Defense

>>

Asia Pacific Biodefense Market


Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

Report code: SDMRFI1298133 | Industry: Aerospace & Defense | Published On: 2020-06-30


Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact.

Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications.

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines

Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
Antibiotics
Masks
Other Products

Based on Sales Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Online Sales
• Offline Sales

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Military
• Civilian

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction  6
1.1  Industry  Definition  and  Research  Scope  6
1.1.1  Industry  Definition  6
1.1.2  Research  Scope  7
1.2  Research  Methodology  10
1.2.1  Overview  of  Market  Research  Methodology  10
1.2.2  Market  Assumption  11
1.2.3  Secondary  Data  11
1.2.4  Primary  Data  11
1.2.5  Data  Filtration  and  Model  Design  13
1.2.6  Market  Size/Share  Estimation  14
1.2.7  Research  Limitations  15
1.3  Executive  Summary  16

2  Market  Overview  and  Dynamics  18
2.1  Market  Size  and  Forecast  18
2.2  Major  Growth  Drivers  19
2.3  Market  Restraints  and  Challenges  22
2.4  Emerging  Opportunities  and  Market  Trends  25
2.5  Porter’s  Fiver  Forces  Analysis  29

3  Segmentation  of  Asia  Pacific  Market  by  Product  33
3.1  Market  Overview  by  Product  33
3.2  Vaccines  35
3.2.1  Anthrax  38
3.2.2  Smallpox  39
3.2.3  Botulism  40
3.2.4  Nuclear/Radiation  41
3.2.5  E-Bola  42
3.2.6  Zika  43
3.2.7  Other  Vaccines  44
3.3  Biothreat  Detection  Devices  45
3.4  Antibiotics  47
3.5  Masks  48
3.6  Other  Products  49

4  Segmentation  of  Asia  Pacific  Market  by  Sales  Channel  50
4.1  Market  Overview  by  Sales  Channel  50
4.2  Online  Sales  52
4.3  Offline  Sales  53

5  Segmentation  of  Asia  Pacific  Market  by  Application  54
5.1  Market  Overview  by  Application  54
5.2  Military  56
5.3  Civilian  57

6  Asia-Pacific  Market  2019-2030  by  Country  58
6.1  Overview  of  Asia-Pacific  Market  58
6.2  Japan  61
6.3  China  64
6.4  Australia  66
6.5  India  68
6.6  South  Korea  70
6.7  Rest  of  APAC  Region  72

7  Competitive  Landscape  74
7.1  Overview  of  Key  Vendors  74
7.2  New  Product  Launch,  Partnership,  Investment,  and  M&A  77
7.3  Company  Profiles  78
Achaogen,  Inc.  78
Alexeter  Technologies  LLC  80
Alnylam  Pharmaceuticals,  Inc.  81
Altimmune,  Inc.  82
Bavarian  Nordic  AS  83
BioFactura,  Inc.  84
Cleveland  Biolabs,  Inc.  85
Dynavax  Technologies  Inc  86
Dynport  Vaccine  Company  LLC  (DVC)  87
Elusys  Therapeutics,  Inc.  88
Emergent  BioSolutions  Inc  89
General  Dynamics  Corp.  90
GlaxoSmithKline  Plc  91
Ichor  Medical  Systems  92
Mediimmune  (AstraZeneca)  93
Nanotherapeutics,  Inc.  94
Ology  Bioscience  95
PathSensors  Inc  96
Pluristem  Therapeutics  97
Sanofi  Pasteur  Ltd.  98
SIGA  Technologies,  Inc.  99
Soligenix,  Inc.  100
Xoma  Corporation  101

8  Investing  in  Asia  Pacific  Market:  Risk  Assessment  and  Management  102
8.1  Risk  Evaluation  of  Asia  Pacific  Market  102
8.2  Critical  Success  Factors  (CSFs)  105
Related  Reports  and  Products  108
Table 1. Snapshot of Asia Pacific Biodefense Market, 2019-2030 17
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Biodefense Market 25
Table 3. Asia Pacific Biodefense Market by Product, 2019-2030, $ mn 33
Table 4. Asia Pacific Biodefense Market: Vaccines by Application, 2019-2030, $ mn 36
Table 5. List of Biodefense Vaccine Pipelines 37
Table 6. Asia Pacific Biodefense Market: Vaccines Biothreat Detection Devices by Type, 2019-2030, $ mn 46
Table 7. Asia Pacific Biodefense Market by Sales Channel, 2019-2030, $ mn 50
Table 8. Asia Pacific Market by Application, 2019-2030, $ mn 54
Table 9. APAC Biodefense Market by Country, 2019-2030, $ mn 59
Table 10. Japan Biodefense Market by Product, 2019-2030, $ mn 63
Table 11. Japan Biodefense Market by Sales Channel, 2019-2030, $ mn 63
Table 12. Japan Biodefense Market by Application, 2019-2030, $ mn 63
Table 13. China Biodefense Market by Product, 2019-2030, $ mn 65
Table 14. China Biodefense Market by Sales Channel, 2019-2030, $ mn 65
Table 15. China Biodefense Market by Application, 2019-2030, $ mn 65
Table 16. Australia Biodefense Market by Product, 2019-2030, $ mn 67
Table 17. Australia Biodefense Market by Sales Channel, 2019-2030, $ mn 67
Table 18. Australia Biodefense Market by Application, 2019-2030, $ mn 67
Table 19. India Biodefense Market by Product, 2019-2030, $ mn 69
Table 20. India Biodefense Market by Sales Channel, 2019-2030, $ mn 69
Table 21. India Biodefense Market by Application, 2019-2030, $ mn 69
Table 22. South Korea Biodefense Market by Product, 2019-2030, $ mn 71
Table 23. South Korea Biodefense Market by Sales Channel, 2019-2030, $ mn 71
Table 24. South Korea Biodefense Market by Application, 2019-2030, $ mn 71
Table 25. Biodefense Market in Rest of APAC by Country, 2019-2030, $ mn 73
Table 26. Achaogen, Inc.: Company Snapshot 78
Table 27. Achaogen, Inc.: Business Segmentation 78
Table 28. Achaogen, Inc.: Product Portfolio 79
Table 29. Achaogen, Inc.: Revenue, 2016-2018, $ mn 79
Table 30. Achaogen, Inc.: Recent Developments 79
Table 31. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 103
Table 32. Critical Success Factors and Key Takeaways 106
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT